Arbutus Biopharma Corp (ABUS)
3.64
+0.01
(+0.28%)
USD |
NASDAQ |
Nov 15, 16:00
3.64
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Research and Development Expense (TTM): 62.79M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 62.79M |
| June 30, 2024 | 68.69M |
| March 31, 2024 | 70.83M |
| December 31, 2023 | 73.70M |
| September 30, 2023 | 79.08M |
| June 30, 2023 | 78.97M |
| March 31, 2023 | 84.22M |
| December 31, 2022 | 84.41M |
| September 30, 2022 | 80.67M |
| June 30, 2022 | 77.32M |
| March 31, 2022 | 70.18M |
| December 31, 2021 | 65.50M |
| September 30, 2021 | 62.68M |
| June 30, 2021 | 58.04M |
| March 31, 2021 | 52.70M |
| December 31, 2020 | 49.34M |
| September 30, 2020 | 45.36M |
| June 30, 2020 | 51.03M |
| March 31, 2020 | 53.30M |
| December 31, 2019 | 57.60M |
| September 30, 2019 | 56.25M |
| June 30, 2019 | 55.08M |
| March 31, 2019 | 58.70M |
| December 31, 2018 | 57.93M |
| Date | Value |
|---|---|
| September 30, 2018 | 64.69M |
| June 30, 2018 | 63.66M |
| March 31, 2018 | 62.75M |
| December 31, 2017 | 62.68M |
| September 30, 2017 | 62.01M |
| June 30, 2017 | 62.21M |
| March 31, 2017 | 61.98M |
| December 31, 2016 | 61.25M |
| September 30, 2016 | 59.00M |
| June 30, 2016 | 59.62M |
| March 31, 2016 | 54.09M |
| December 31, 2015 | 51.50M |
| September 30, 2015 | 48.50M |
| June 30, 2015 | 41.46M |
| March 31, 2015 | 41.07M |
| December 31, 2014 | 38.71M |
| September 30, 2014 | 33.78M |
| June 30, 2014 | 29.98M |
| March 31, 2014 | 25.60M |
| December 31, 2013 | 21.46M |
| September 30, 2013 | 21.55M |
| June 30, 2013 | 19.19M |
| March 31, 2013 | 17.79M |
| December 31, 2012 | 17.87M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
45.36M
Minimum
Sep 2020
84.41M
Maximum
Dec 2022
66.32M
Average
67.09M
Median
Research and Development Expense (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 779.92M |
| Amicus Therapeutics Inc | 114.20M |
| Ionis Pharmaceuticals Inc | 912.60M |
| GlycoMimetics Inc | 22.89M |
| FibroGen Inc | 185.40M |